MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
PCL Health is a Business-to-Business (B2B) Software-as-a-Service (SaaS) entity that aims to bring hospital-level care to anyone remotely. It asserts that the correct use of remote monitoring can reduce mortality by up to 45%. PCL Health intends to become a contender in the remote healthcare market that is set to touch $30 billion by 2023. It has developed CE rated medical-grade devices that use health algorithms combined with sensors and its proprietary range of apps to allow family members to proactively monitor the health of their loved ones, alongside carers and doctors, remotely. PCL Health has completed two pilots with 65 people and received a Letter Of Intent (LOI) from a National Health Service (NHS) Trust for a clinical trial. It won the 'Innovative Startup' competition at the 2019 Healthcare Unblocked event. PCL Health will use the investment for technology enhancement, running further pilot studies, and working capital.
days to go:
Expired
investment:
£394,680
Q Doctor aims at changing the NHS care delivery with the help of video consulting to benefit patients and clinicians. The company is focusing on delivering a model that keeps modernised NHS care free of charge for the patients. The video solution plugs NHS clinicians to the existing NHS infrastructure and allows them to connect to the NHS patients digitally. With the proceeds, Q Doctor will fulfil its strategy for 2020. It will deploy the funds into labour, development, operations, marketing, and contingency funds.
days to go:
Expired
investment:
£1,386,200
Pass the Keys is a leading short-let tech platform operating in 20 cities across the UK. Till date, the company has hosted 30,000+ guests and earned £15 million for its hosts. The company lists a landlord's property on appropriate portals, finds relevant guests for an event or function, looks after their needs, and even takes care of cleaning up the venue after an event. The company's end-to-end technology automates the majority of the tasks such as job scheduling, invoicing, calendar syncing, and pricing with reliable support staff ready to assist with any eventuality. The company has achieved good ratings on Google reviews, Trustpilot and Glassdoor. The company will use 50% of the investment to expand its franchise, 30% for product development, and 20% for training personnel and supporting infrastructure.
days to go:
Expired
investment:
£1,069,632
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.
days to go:
Expired
investment:
£691,497
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
days to go:
Expired
investment:
Withheld
With support from the founders of Bulldog Skincare, Zoopla and Love Film, VITL's aim is to improve the nation's health by offering vitamin packs that are fully personalised to the customer. VITL uses artificial intelligence to decipher which nutrients a person needs to ensure a healthy lifestyle. Effectively cutting out the cost of a private nutritionist.
days to go:
Expired
investment:
£908,950
Pawprint is a behavioural change platform that is on a mission to fight climate change. The platform allows people to measure, understand and reduce their carbon footprint, and fight ‘climate change’ by giving people bite-sized chunks to focus on. It aims to be the middleman, helping brands reach and understand their audience by offering these brands personalised challenges to help their reduce carbon footprint. The market for behavioural change platforms is slowly gaining solid traction with established brands such as Fitbit, Strava, and Calm. Pawprint aims to capitalise on this collective concern and deliver services that help mitigate those concerns.
days to go:
Expired
investment:
£352,440
nu:move Group is an award-winning Hybrid nationwide online estate agency. The company offers its customers a simple, online process to sell and let their property. The business is built on an ethos of modern innovation and traditional values by blending online and high street estate agency services seamlessly. The company offers a full set of estate agency services and affordable sales packages. nu:move Group has marketed more than 10,000 properties globally that are worth £3Bn and has received a 5 Star Trust Pilot Rating. The company has won The Negotiator 'Hybrid Estate Agent of the Year Award 2019.' 40% of the investment will be used for brand awareness, 30% for technology, 20% for franchise network training and expansion, and 105 for staffing at nu:move HQ.
days to go:
Expired
investment:
£153,342
